{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:30:27Z","timestamp":1791304227840,"version":"4.3.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006256","name":"Universit\u00e0 degli Studi dell\u2019Aquila","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006256","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40292-020-00414-w","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T16:03:58Z","timestamp":1602518638000},"page":"539-546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The role of Immunity in Fabry Disease and Hypertension: A Review of a Novel Common Pathway"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4058-0655","authenticated-orcid":false,"given":"Rita","family":"Del Pinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,12]]},"reference":[{"key":"414_CR1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.","journal-title":"Orphanet J Rare Dis"},{"key":"414_CR2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","volume":"124","author":"C Wanner","year":"2018","unstructured":"Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab. 2018;124:189\u2013203.","journal-title":"Mol Genet Metab"},{"key":"414_CR3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249\u201354.","journal-title":"JAMA"},{"key":"414_CR4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s004399900075","volume":"105","author":"BJ Poorthuis","year":"1999","unstructured":"Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999;105:151\u20136.","journal-title":"Hum Genet"},{"key":"414_CR5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79:31\u201340.","journal-title":"Am J Hum Genet"},{"key":"414_CR6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jpeds.2017.06.048","volume":"190","author":"BK Burton","year":"2017","unstructured":"Burton BK, Charrow J, Hoganson GE, Waggoner D, Tinkle B, Braddock SR, et al. Newborn screening for lysosomal storage disorders in Illinois: the initial 15-month experience. J Pediatr. 2017;190:130\u20135.","journal-title":"J Pediatr"},{"key":"414_CR7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/cge.13546","volume":"96","author":"DP Germain","year":"2019","unstructured":"Germain DP, Fouilhoux A, Decramer S, Tardieu M, Pillet P, Fila M, et al. Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients. Clin Genet. 2019;96:107\u201317.","journal-title":"Clin Genet"},{"key":"414_CR8","first-page":"83","volume":"34","author":"P Bolasco","year":"2017","unstructured":"Bolasco P, Sitzia I, Murtas S. Fabry disease in Southern Sardinia: epidemiological results from screening in an extensive area. G Ital Nefrol. 2017;34:83\u2013102.","journal-title":"G Ital Nefrol"},{"key":"414_CR9","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/2047487319851301","volume":"27","author":"R Del Pinto","year":"2020","unstructured":"Del Pinto R, Pagliacci S, De Feo M, Grassi D, Ferri C. Italian Society of hypertension and federfarma. Prevalence of hypertension and associated cardiovascular risk factors among pharmacies customers: an Italian nationwide epidemiological survey. Eur J Prev Cardiol. 2020;27:1228\u201330.","journal-title":"Eur J Prev Cardiol"},{"key":"414_CR10","doi-asserted-by":"crossref","first-page":"c43","DOI":"10.1159\/000320903","volume":"118","author":"G Jain","year":"2011","unstructured":"Jain G, Warnock DG. Blood pressure, proteinuria and nephropathy in Fabry disease. Nephron Clin Pract. 2011;118:c43\u20138.","journal-title":"Nephron Clin Pract"},{"key":"414_CR11","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.2174\/13816128113199990352","volume":"19","author":"A Tuttolomondo","year":"2013","unstructured":"Tuttolomondo A, Pecoraro R, Simonetta I, Miceli S, Pinto A, Licata G. Anderson-Fabry disease: a multiorgan disease. Curr Pharm Des. 2013;19:5974\u201396.","journal-title":"Curr Pharm Des"},{"key":"414_CR12","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1161\/01.CIR.0000061952.27445.A0","volume":"107","author":"M Pieroni","year":"2003","unstructured":"Pieroni M, Chimenti C, Ricci R, Sale P, Russo MA, Frustaci A. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation. 2003;107:1978\u201384.","journal-title":"Circulation"},{"key":"414_CR13","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.ATV.0000209649.60409.38","volume":"26","author":"F Barbey","year":"2006","unstructured":"Barbey F, Brakch N, Linhart A, Rosenblatt-Velin N, Jeanrenaud X, Qanadli S, et al. Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler Thromb Vasc Biol. 2006;26:839\u201344.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"414_CR14","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1161\/01.CIR.54.5.818","volume":"54","author":"RJ Desnick","year":"1976","unstructured":"Desnick RJ, Blieden LC, Sharp HL, Hofschire PJ, Moller JH. Cardiac valvular anomalies in Fabry disease. Clinical, morphologic, and biochemical studies. Circulation. 1976;54:818\u201325.","journal-title":"Circulation"},{"key":"414_CR15","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA. 2008;105:2812\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"414_CR16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehp387","volume":"31","author":"N Brakch","year":"2010","unstructured":"Brakch N, Dormond O, Bekri S, Golshayan D, Correvon M, Mazzolai L, et al. Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. Eur Heart J. 2010;31:67\u201376.","journal-title":"Eur Heart J"},{"key":"414_CR17","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2009.10.004","volume":"99","author":"SM Rombach","year":"2010","unstructured":"Rombach SM, Twickler TB, Aerts JMFG, Linthorst GE, Wijburg FA, Hollak CEM. Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab. 2010;99:99\u2013108.","journal-title":"Mol Genet Metab"},{"key":"414_CR18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/sj.jhh.1002101","volume":"21","author":"P Dandona","year":"2007","unstructured":"Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens. 2007;21:20\u20137.","journal-title":"J Hum Hypertens"},{"key":"414_CR19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0008-6363(99)00183-2","volume":"44","author":"H Zhang","year":"1999","unstructured":"Zhang H. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells role of membrane-bound NADH-\/NADPH-oxidases. Cardiovasc Res. 1999;44:215\u201322.","journal-title":"Cardiovasc Res"},{"key":"414_CR20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.phrs.2017.03.017","volume":"120","author":"VC Biancardi","year":"2017","unstructured":"Biancardi VC, Bomfim GF, Reis WL, Al-Gassimi S, Nunes KP. The interplay between Angiotensin II, TLR4 and hypertension. Pharmacol Res. 2017;120:88\u201396.","journal-title":"Pharmacol Res"},{"key":"414_CR21","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/hy1201.100589","volume":"38","author":"M Ruiz-Ortega","year":"2001","unstructured":"Ruiz-Ortega M, Lorenzo O, Rup\u00e9rez M, Esteban V, Suzuki Y, Mezzano S, et al. Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension. 2001;38:1382\u20137.","journal-title":"Hypertension"},{"key":"414_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19123701","author":"R Del Pinto","year":"2018","unstructured":"Del Pinto R, Ferri C. Inflammation-accelerated senescence and the cardiovascular system: mechanisms and perspectives. Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19123701.","journal-title":"Int J Mol Sci"},{"key":"414_CR23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2000.00160.x","author":"S Nakamura","year":"2000","unstructured":"Nakamura S, Nakamura I, Ma L, Vaughan DE, Fogo AB. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo1. Kidney Int. 2000. https:\/\/doi.org\/10.1046\/j.1523-1755.2000.00160.x.","journal-title":"Kidney Int"},{"key":"414_CR24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2008.06.016","volume":"95","author":"J-S Shen","year":"2008","unstructured":"Shen J-S, Meng X-L, Moore DF, Quirk JM, Shayman JA, Schiffmann R, et al. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab. 2008;95:163\u20138.","journal-title":"Mol Genet Metab"},{"key":"414_CR25","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bbadis.2011.11.001","volume":"1822","author":"GB Biancini","year":"2012","unstructured":"Biancini GB, Vanzin CS, Rodrigues DB, Deon M, Ribas GS, Barschak AG, et al. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. Biochim Biophys Acta. 2012;1822:226\u201332.","journal-title":"Biochim Biophys Acta"},{"key":"414_CR26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","volume":"122","author":"P Rozenfeld","year":"2017","unstructured":"Rozenfeld P, Feriozzi S. Contribution of inflammatory pathways to Fabry disease pathogenesis. Mol Genet Metab. 2017;122:19\u201327.","journal-title":"Mol Genet Metab"},{"key":"414_CR27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1161\/HYPERTENSIONAHA.110.163576","volume":"57","author":"DG Harrison","year":"2011","unstructured":"Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57:132\u201340.","journal-title":"Hypertension"},{"key":"414_CR28","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1681\/ASN.2015050562","volume":"27","author":"U Wenzel","year":"2016","unstructured":"Wenzel U, Turner JE, Krebs C, Kurts C, Harrison DG, Ehmke H. Immune mechanisms in arterial hypertension. J Am Soc Nephrol. 2016;27:677\u201386.","journal-title":"J Am Soc Nephrol"},{"key":"414_CR29","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0952-7915(00)00124-2","volume":"12","author":"J Galon","year":"2000","unstructured":"Galon J, Aksentijevich I, McDermott MF, O\u2019Shea JJ, Kastner DL. TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol. 2000;12:479\u201386.","journal-title":"Curr Opin Immunol"},{"key":"414_CR30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2016.05.001","volume":"138","author":"HM Hoffman","year":"2016","unstructured":"Hoffman HM, Broderick L. The role of the inflammasome in patients with autoinflammatory diseases. J Allergy Clin Immunol. 2016;138:3\u201314.","journal-title":"J Allergy Clin Immunol"},{"key":"414_CR31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ymgme.2013.02.003","volume":"109","author":"PN De Francesco","year":"2013","unstructured":"De Francesco PN, Mucci JM, Ceci R, Fossati CA, Rozenfeld PA. Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide. Mol Genet Metab. 2013;109:93\u20139.","journal-title":"Mol Genet Metab"},{"key":"414_CR32","doi-asserted-by":"crossref","first-page":"H184","DOI":"10.1152\/ajpheart.00328.2013","volume":"306","author":"CG McCarthy","year":"2014","unstructured":"McCarthy CG, Goulopoulou S, Wenceslau CF, Spitler K, Matsumoto T, Webb RC. Toll-like receptors and damage-associated molecular patterns: novel links between inflammation and hypertension. Am J Physiol Heart Circ Physiol. 2014;306:H184\u201396.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"414_CR33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000179322","volume":"1","author":"FN White","year":"1964","unstructured":"White FN, Grollman A. Autoimmune factors associated with infarction of the kidney. Nephron. 1964;1:93\u2013102.","journal-title":"Nephron"},{"key":"414_CR34","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3389\/fphys.2019.00655","volume":"10","author":"KP Nunes","year":"2019","unstructured":"Nunes KP, de Oliveira AA, Lima VV, Webb RC. Toll-like receptor 4 and blood pressure: lessons from animal studies. Front Physiol. 2019;10:655.","journal-title":"Front Physiol"},{"key":"414_CR35","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1042\/CS20110523","volume":"122","author":"GF Bomfim","year":"2012","unstructured":"Bomfim GF, Dos Santos RA, Oliveira MA, Giachini FR, Akamine EH, Tostes RC, et al. Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats. Clin Sci. 2012;122:535\u201343.","journal-title":"Clin Sci"},{"key":"414_CR36","doi-asserted-by":"crossref","first-page":"e0142456","DOI":"10.1371\/journal.pone.0142456","volume":"10","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Peng W, Ao X, Dai H, Yuan L, Huang X, et al. TAK-242, a toll-like receptor 4 antagonist, protects against aldosterone-induced cardiac and renal injury. PLoS One. 2015;10:e0142456.","journal-title":"PLoS One"},{"key":"414_CR37","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.1038\/s41598-017-06484-6","volume":"7","author":"S Pushpakumar","year":"2017","unstructured":"Pushpakumar S, Ren L, Kundu S, Gamon A, Tyagi SC, Sen U. Toll-like receptor 4 deficiency reduces oxidative stress and macrophage mediated inflammation in hypertensive kidney. Sci Rep. 2017;7:6349.","journal-title":"Sci Rep"},{"key":"414_CR38","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/cvr\/cvt265","volume":"101","author":"D Sollinger","year":"2014","unstructured":"Sollinger D, Ei\u00dfler R, Lorenz S, Strand S, Chmielewski S, Aoqui C, et al. Damage-associated molecular pattern activated toll-like receptor 4 signalling modulates blood pressure in L-NAME-induced hypertension. Cardiovasc Res. 2014;101:464\u201372.","journal-title":"Cardiovasc Res"},{"key":"414_CR39","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000218173","volume":"23","author":"Y Ji","year":"2009","unstructured":"Ji Y, Liu J, Wang Z, Liu N. Angiotensin II induces inflammatory response partly via toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells. Cell Physiol Biochem. 2009;23:265\u201376.","journal-title":"Cell Physiol Biochem"},{"key":"414_CR40","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/hr.2015.55","volume":"38","author":"T Nakashima","year":"2015","unstructured":"Nakashima T, Umemoto S, Yoshimura K, Matsuda S, Itoh S, Murata T, et al. TLR4 is a critical regulator of angiotensin II-induced vascular remodeling: the roles of extracellular SOD and NADPH oxidase. Hypertens Res. 2015;38:649\u201355.","journal-title":"Hypertens Res"},{"key":"414_CR41","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1111\/bph.13117","volume":"172","author":"R Hernanz","year":"2015","unstructured":"Hernanz R, Mart\u00ednez-Revelles S, Palacios R, Mart\u00edn A, Cachofeiro V, Aguado A, et al. Toll-like receptor 4 contributes to vascular remodelling and endothelial dysfunction in angiotensin II-induced hypertension. Br J Pharmacol. 2015;172:3159\u201376.","journal-title":"Br J Pharmacol"},{"key":"414_CR42","doi-asserted-by":"crossref","first-page":"e104020","DOI":"10.1371\/journal.pone.0104020","volume":"9","author":"PR De Batista","year":"2014","unstructured":"De Batista PR, Palacios R, Mart\u00edn A, Hernanz R, M\u00e9dici CT, Silva MASC, et al. Toll-like receptor 4 upregulation by angiotensin II contributes to hypertension and vascular dysfunction through reactive oxygen species production. PLoS One. 2014;9:e104020.","journal-title":"PLoS One"},{"key":"414_CR43","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.puhe.2018.03.011","volume":"158","author":"R Del Pinto","year":"2018","unstructured":"Del Pinto R, Pietropaoli D, Russomando U, Evangelista P, Ferri C. Health status of Afro-Asian refugees in an Italian urban area: a cross-sectional monocentric study. Public Health. 2018;158:176\u201382.","journal-title":"Public Health"},{"key":"414_CR44","doi-asserted-by":"crossref","first-page":"e0140627","DOI":"10.1371\/journal.pone.0140627","volume":"10","author":"J Kr\u00e4mer","year":"2015","unstructured":"Kr\u00e4mer J, Bijnens B, St\u00f6rk S, Ritter CO, Liu D, Ertl G, et al. Left ventricular geometry and blood pressure as predictors of adverse progression of Fabry cardiomyopathy. PLoS One. 2015;10:e0140627.","journal-title":"PLoS One"},{"key":"414_CR45","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/HJH.0000000000002231","volume":"38","author":"R Del Pinto","year":"2020","unstructured":"Del Pinto R, Wright JT, Monaco A, Pietropaoli D, Ferri C. Vitamin D and blood pressure control among hypertensive adults: results from NHANES 2001\u20132014. J Hypertens. 2020;38:150\u20138.","journal-title":"J Hypertens"},{"key":"414_CR46","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/JPER.19-0046","volume":"90","author":"D Pietropaoli","year":"2019","unstructured":"Pietropaoli D, Del Pinto R, Ferri C, Ortu E, Monaco A. Definition of hypertension-associated oral pathogens in NHANES. J Periodontol. 2019;90:866\u201376.","journal-title":"J Periodontol"},{"key":"414_CR47","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40292-020-00392-z","volume":"27","author":"R Del Pinto","year":"2020","unstructured":"Del Pinto R, Pietropaoli D, Munoz-Aguilera E, D\u2019Aiuto F, Czesnikiewicz-Guzik M, Monaco A, et al. Periodontitis and hypertension: is the association causal? High Blood Press Cardiovasc Prev. 2020;27:281\u20139.","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"414_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2020.07.013","author":"F Mai","year":"2020","unstructured":"Mai F, Del Pinto R, Ferri C. COVID-19 and cardiovascular diseases. J Cardiol. 2020. https:\/\/doi.org\/10.1016\/j.jjcc.2020.07.013.","journal-title":"J Cardiol"},{"key":"414_CR49","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1161\/HYPERTENSIONAHA.118.11528","volume":"72","author":"D Pietropaoli","year":"2018","unstructured":"Pietropaoli D, Del Pinto R, Ferri C, Wright JT Jr, Giannoni M, Ortu E, et al. Poor oral health and blood pressure control among US hypertensive adults. Hypertension. 2018;72:1365\u201373.","journal-title":"Hypertension"},{"key":"414_CR50","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002514","author":"D Pietropaoli","year":"2020","unstructured":"Pietropaoli D, Monaco A, D\u2019Aiuto F, Mu\u00f1oz Aguilera E, Ortu E, Giannoni M, et al. Active gingival inflammation is linked to hypertension. J Hypertens. 2020. doi:https:\/\/doi.org\/10.1097\/HJH.0000000000002514.","journal-title":"J Hypertens"},{"key":"414_CR51","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.amjhyper.2006.01.011","volume":"19","author":"J Kleinert","year":"2006","unstructured":"Kleinert J, Dehout F, Schwarting A, de Lorenzo AG, Ricci R, Kampmann C, et al. Prevalence of uncontrolled hypertension in patients with Fabry disease. Am J Hypertens. 2006;19:782\u20137.","journal-title":"Am J Hypertens"},{"key":"414_CR52","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.ajkd.2018.12.044","volume":"74","author":"E Ku","year":"2019","unstructured":"Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: core curriculum 2019. Am J Kidney Dis. 2019;74:120\u201331.","journal-title":"Am J Kidney Dis"},{"key":"414_CR53","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","volume":"57","author":"MR Patel","year":"2011","unstructured":"Patel MR, Cecchi F, Cizmarik M, Kantola I, Linhart A, Nicholls K, et al. Cardiovascular events in patients with fabry disease natural history data from the fabry registry. J Am Coll Cardiol. 2011;57:1093\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"414_CR54","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40292-019-00323-7","volume":"26","author":"R Del Pinto","year":"2019","unstructured":"Del Pinto R, Grassi D, Properzi G, Desideri G, Ferri C. Low density lipoprotein (LDL) cholesterol as a causal role for atherosclerotic disease: potential role of PCSK9 inhibitors. High Blood Press Cardiovasc Prev. 2019;26:199\u2013207.","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"414_CR55","doi-asserted-by":"crossref","first-page":"100454","DOI":"10.1016\/j.ymgmr.2019.100454","volume":"19","author":"DP Germain","year":"2019","unstructured":"Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A, et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts. Mol Genet Metab Rep. 2019;19:100454.","journal-title":"Mol Genet Metab Rep"},{"key":"414_CR56","unstructured":"(2020). http:\/\/garrod.ca\/wp-content\/uploads\/2019\/04\/Canadian-Fabry-Treatment-Guidelines-2018-final.pdf.\u00a0Accessed 13 Aug 2020"},{"key":"414_CR57","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nrendo.2015.6","volume":"11","author":"CA Romero","year":"2015","unstructured":"Romero CA, Orias M, Weir MR. Novel RAAS agonists and antagonists: clinical applications and controversies. Nat Rev Endocrinol. 2015;11:242\u201352.","journal-title":"Nat Rev Endocrinol"},{"key":"414_CR58","doi-asserted-by":"crossref","first-page":"305087","DOI":"10.1155\/2008\/305087","volume":"2008","author":"G Desideri","year":"2008","unstructured":"Desideri G, Grassi D, Croce G, Bocale R, Tiberti S, Evangelista S, et al. Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: evidence of an oxidant-sensitive pathway. Mediators Inflamm. 2008;2008:305087.","journal-title":"Mediators Inflamm"},{"key":"414_CR59","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1161\/01.ATV.0000021412.56621.A2","volume":"22","author":"AR Brasier","year":"2002","unstructured":"Brasier AR, Recinos A 3rd, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol. 2002;22:1257\u201366.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"414_CR60","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1750-1172-8-116","volume":"8","author":"F Weidemann","year":"2013","unstructured":"Weidemann F, Sanchez-Ni\u00f1o MD, Politei J, Oliveira J-P, Wanner C, Warnock DG, et al. Fibrosis: a key feature of Fabry disease with potential therapeutic implications. Orphanet J Rare Dis. 2013;8:116.","journal-title":"Orphanet J Rare Dis"},{"key":"414_CR61","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40292-018-0290-z","volume":"26","author":"R Del Pinto","year":"2019","unstructured":"Del Pinto R, Ferri C. Hypertension management at older age: an update. High Blood Press Cardiovasc Prev. 2019;26:27\u201336.","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"414_CR62","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jash.2016.08.005","volume":"10","author":"RR Townsend","year":"2016","unstructured":"Townsend RR, Chang TI, Cohen DL, Cushman WC, Evans GW, Glasser SP, et al. Orthostatic changes in systolic blood pressure among SPRINT participants at baseline. J Am Soc Hypertens. 2016;10:847\u201356.","journal-title":"J Am Soc Hypertens"},{"key":"414_CR63","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1681\/ASN.2006121400","volume":"18","author":"H Tahir","year":"2007","unstructured":"Tahir H, Jackson LL, Warnock DG. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol. 2007;18:2609\u201317.","journal-title":"J Am Soc Nephrol"},{"key":"414_CR64","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1097\/HJH.0b013e328336a077","volume":"28","author":"MJ Hilz","year":"2010","unstructured":"Hilz MJ, Marthol H, Schwab S, Kolodny EH, Brys M, Stemper B. Enzyme replacement therapy improves cardiovascular responses to orthostatic challenge in Fabry patients. J Hypertens. 2010;28:1438\u201348.","journal-title":"J Hypertens"},{"key":"414_CR65","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1097\/HJH.0000000000002508","volume":"38","author":"L Zanoli","year":"2020","unstructured":"Zanoli L, Briet M, Empana JP, Cunha PG, M\u00e4ki-Pet\u00e4j\u00e4 KM, Protogerou AD, et al. Vascular consequences of inflammation: a position statement from the ESH working group on vascular structure and function and the ARTERY society. J Hypertens. 2020;38:1682\u201398.","journal-title":"J Hypertens"}],"container-title":["High Blood Pressure & Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-020-00414-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40292-020-00414-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-020-00414-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T12:57:55Z","timestamp":1634043475000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40292-020-00414-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,12]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["414"],"URL":"https:\/\/doi.org\/10.1007\/s40292-020-00414-w","relation":{},"ISSN":["1120-9879","1179-1985"],"issn-type":[{"value":"1120-9879","type":"print"},{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,12]]},"assertion":[{"value":"14 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi dell\u2019Aquila within the CRUI-CARE Agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no conflict of interest statement.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}